Pharvaris Validates Clinical Endpoints for Ultra-Rare AAE-C1INH Treatment
Event summary
- Pharvaris published results of the first in-depth qualitative study on AAE-C1INH, an ultra-rare disease with no approved therapies.
- Study findings informed the design and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) investigating deucrictibant.
- The study validated Patient Global Impression of Change (PGI-C) as a meaningful measure for assessing treatment benefits in AAE-C1INH.
- All participants relied on off-label therapies, underscoring the unmet needs in this condition.
The big picture
Pharvaris' study highlights the critical gap in treating AAE-C1INH, an ultra-rare condition with no approved therapies. The validation of patient-reported outcomes strengthens the company's clinical trial framework, aligning with FDA guidance and potentially accelerating regulatory approval. This positions Pharvaris to address a significant unmet need in bradykinin-mediated angioedema, a niche but high-value segment of the biopharmaceutical market.
What we're watching
- Regulatory Alignment
- Whether Pharvaris can sustain FDA-aligned clinical trial designs to expedite approval for deucrictibant.
- Execution Risk
- The pace at which the Phase 3 CREAATE study progresses and whether it meets primary endpoints.
- Market Opportunity
- How Pharvaris positions deucrictibant in an ultra-rare disease space with significant unmet needs.